Intrinsic features of the cancer cell as drivers of immune checkpoint blockade response and refractoriness

Abstract

Immune checkpoint blockade represents the latest revolution in cancer treatment by substantially increasing patients’ lifetime and quality of life in multiple neoplastic pathologies. However, this new avenue of cancer management appeared extremely beneficial in a minority of cancer types and the sub-population of patients that would benefit from such therapies remain difficult to predict. In this review of the literature, we have summarized important knowledge linking cancer cell characteristics with the response to immunotherapy. Mostly focused on lung cancer, our objective was to illustrate how cancer cell diversity inside a well-defined pathology might explain sensitivity and refractoriness to immunotherapies. We first discuss how genomic instability, epigenetics and innate immune signaling could explain differences in the response to immune checkpoint blockers. Then, in a second part we detailed important notions suggesting that altered cancer cell metabolism, specific oncogenic signaling, tumor suppressor loss as well as tight control of the cGAS/STING pathway in the cancer cells can be associated with resistance to immune checkpoint blockade. At the end, we discussed recent evidences that could suggest that immune checkpoint blockade as first line therapy might shape the cancer cell clones diversity and give rise to the appearance of novel resistance mechanisms.

The Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Breast Cancer Are Regulated by N-Linked Glycosylation-Dependent Activation of STAT3 and STAT1

“…Immunotherapies, whose aim is to potentiate anti-tumor immune activities, are now being implemented in the treatment of melanoma and of tumors with high mutation rates and DNA mismatch repair defects [1][2][3]. In breast cancer, immune checkpoint blockades (ICBs) have been introduced to the treatment of triple-negative breast cancers (TNBCs) that demonstrate relatively high genomic instability [4,5].…”

Mutation of neurotrophic tyrosine receptor kinase can promote pan-cancer immunity and the efficacy of immunotherapy

“…The major intrinsic immune response included high tumor immunogenicity, activation of the antigen-processing machinery, and the over-expression of costimulatory molecules [ 6 ]. As shown in Fig.…”